Вторичная профилактика ишемической болезни сердца и ингибиторы PCSK9


DOI: https://dx.doi.org/10.18565/therapy.2021.2.105-111

А.А. Кузнецов, Г.С. Маль

1) ГБУЗ МО «Московская областная больница им. проф. Розанова В.Н.», Московская область, г. Пушкино; 2) ФГБОУ ВО «Курский государственный медицинский университет» Минздрава России
Аннотация. Ишемическая болезнь сердца (ИБС) на протяжении многих лет является основной причиной смертности населения во всем мире. Длительное время ведущим методом вторичной профилактики гиперхолестеринемии служило применение ингибиторов синтеза холестерина в печени – статинов. Однако только 70% пациентов достигали целевого уровня атерогенных липидов на фоне их приема, поэтому долгие годы проводился поиск новых более эффективных гиполипидемических препаратов. В 2015 г. впервые были одобрены для клинического применения ингибиторы плазменного белка PCSK9, применение которых позволяет достичь целевой уровень липидных показателей более чем у 90% пациентов
Ключевые слова: ингибиторы PCSK9, ишемическая болезнь сердца, атеросклероз, алирокумаб, эвалокумаб
Полный текст статьи доступен
в "Библиотеке Врача"

Литература


  1. A global brief on hypertension. Silent killer, global public health crisis. World Health Organization. 2013. Available at: https://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en (date of access – 01.02.2021).

  2. Available at: https://tass.ru/obschestvo/6627091 (date of access – 01.02.2021) (In Russ.)].

  3. Baigent C., Blackwell L., Emberson J. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670–81. doi: 10.1016/S0140-6736(10)61350-5.

  4. Pinho-Gomes A.C., Azevedo L., Ahn J.M. et al. Compliance with guideline-directed medical therapy in contemporary coronary revascularization trials. J Am Coll Cardiol, 2018; 71(6): 591–602. doi: 10.1016/j.jacc.2017.11.068.

  5. Goyal A., Alexander J.H., Hafley G.E. et al. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. Ann Thorac Surg. 2007; 83(3): 993–1001. doi: 10.1016/j.athoracsur.2006.10.046.

  6. Iqbal J., Zhang Y.J., Holmes D.R. et al. Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up. Circulation. 2015; 131(14): 1269–77. doi: 10.1161/CIRCULATIONAHA.114.013042.

  7. Al-Lamee R., Thompson D., Dehbi H.M. et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018; 391(10115): 31–40. doi: 10.1016/S0140-6736(17)32714-9.

  8. Stone N.J., Robinson J.G., Lichtenstein A.H. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(25 Pt B): 2889–934. doi: 10.1016/j.jacc.2013.11.002. doi: 10.1016/j.jacc.2013.11.002.

  9. Ballantyne C.M., Abate N., Yuan Z. et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) study. Am Heart J. 2005; 149(3): 464–73. doi: 10.1016/j.ahj.2004.11.023.

  10. Kotseva K., Wood D., De Bacquer D. et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016; 23(6): 636–48. doi: 10.1177/2047487315569401.

  11. European Association for Cardiovascular Prevention & Rehabilitation; Reiner Z., Catapano A.L., De Backer G. et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011; 32(14): 1769–818. doi: 10.1093/eurheartj/ehr158.

  12. Accutrend Plus user manual. Roche Diagnostics. 2014.

  13. Goff D.C. Jr, Bertoni A.G., Kramer H. et al. Dyslipidemia prevalence, treatment, and control in the MultiEthnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation. 2006; 113(5): 647–56. doi: 10.1161/CIRCULATIONAHA.105.552737.

  14. Sun G.Z., Li Z., Guo L. et al. High prevalence of dyslipidemia and associated risk factors among rural Chinese adults. Lipids Health Dis. 2014; 13: 189. doi: 10.1186/1476-511X-13-189.

  15. Vegazo O., Banegas J.R., Civeira F. et al.

  16. Plana N., Ibarretxe D., Cabre A. et al. Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception. Clin Investig Arterioscler. 2014; 26(6): 274–84. doi: 10.1016/j.arteri.2014.04.002.

  17. Seidah N.G., Benjannet S., Wickham L. et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003; 100(3): 928–33. doi: 10.1073/pnas.0335507100.

  18. Whayne T.F. Jr. Defining the role of PCSK9 inhibitors in the treatment of hyperlipidemia. Am J Cardiovasc Drugs. 2016; 16(2): 83–92. doi: 10.1007/s40256-015-0150-3.

  19. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020; 41(1): 111–88. doi: 10.1093/eurheartj/ehz455.

  20. Brown M.S., Goldstein J.L. Cholesterol feedback: from Schoenheimer’s bottle to Scap’s MELADL. Lipid Res. 2009; 50 Suppl(Suppl): S15–27. doi: 10.1194/jlr.R800054-JLR200.

  21. Seidah N.G. The proprotein convertases, 20 years later. Methods Mol Biol. 2011; 768: 23–57. doi: 10.1007/978-1-61779-204-5_3.

  22. Denis M., Marcinkiewicz J., Zaid A. et al. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation. 2012; 125(7): 894–901. doi: 10.1161/CIRCULATIONAHA.111.057406.

  23. Chen X.W., Wang H., Bajaj K. et al. SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion. Elife. 2013; 2: e00444. doi: 10.7554/eLife.00444.

  24. Chan J.C., Piper D.E., Cao Q. et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A. 2009; 106(24): 9820–25. doi: 10.1073/pnas.0903849106.

  25. Browning J.D., Horton J.D. Fasting reduces plasma proprotein convertase subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res. 2010; 51(11): 3359–63. doi: 10.1194/jlr.P009860.

  26. Persson L., Cao G., Stahle L. et al. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol. 2010; 30(12): 2666–72. doi: 10.1161/ATVBAHA.110.214130.

  27. Lakoski S.G., Lagace T.A., Cohen J.C. et al. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009; 94(7): 2537–43. doi: 10.1210/jc.2009-0141.

  28. Robinson J.G., Nedergaard B.S., Rogers W.J. et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014; 311(18): 1870–82. doi: 10.1001/jama.2014.4030.

  29. Stroes E., Colquhoun D., Sullivan D. et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014; 63(23): 2541–48. doi: 10.1016/j.jacc.2014.03.019.

  30. Raal F.J., Stein E.A., Dufour R. et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015; 385(9965): 331–40. doi: 10.1016/S0140-6736(14)61399-4.

  31. Sabatine M.S., Giugliano R.P., Keech A.C. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376(18): 1713–1722. doi: 10.1056/NEJMoa1615664.

  32. Koren M.J., Giugliano R.P., Raal F.J. et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014; 129(2): 234–43. doi: 10.1161/CIRCULATIONAHA.113.007012.

  33. Koren M.J., Sabatine M.S., Giugliano R.P. et al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: Results up to 4 years from the OpenLabel OSLER-1 extension study. JAMA Cardiol. 2017; 2(6): 598–607. doi: 10.1001/jamacardio.2017.0747.

  34. Schwartz G.G., Steg P.G., Szarek M. et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018; 379(22): 2097–107. doi: 10.1056/NEJMoa1801174.

  35. Toth P. et al. Presented at the American College of Cardiology. San Diego. 2015.

  36. Ott B.R., Daiello L.A., Dahabreh I.J. et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med. 2015; 30(3): 348–58. doi: 10.1007/s11606-014-3115-3.

  37. Jones P.H., Bays H.E., Chaudhari U. et al. Safety of alirocumab (a PCSK9 monoclonal antibody) from 14 randomized trials. Am J Cardiol. 2016; 118(12): 1805–11. doi: 10.1016/j.amjcard.2016.08.072.


Об авторах / Для корреспонденции

Андрей Александрович Кузнецов, врач-кардиолог ГБУЗ МО «Московская областная больница им. проф. Розанова В.Н.». Адрес: 141206, Московская область, г. Пушкино, ул. Авиационная, д. 35. Тел.: 8 (977) 684-27-15. E-mail: dr.cardiologist.kuznetsov@yandex.ru
Галина Сергеевна Маль, д.м.н., профессор, зав. кафедрой фармакологии ФГБОУ ВО «Курский государственный медицинский университет» Минздрава России. Адрес: 305003, г. Курск, ул. К. Маркса, д. 3. Тел.: 8 (960) 676-16-98. E-mail: mgalina.2013@mail.ru

К содержанию номера

Бионика Медиа